Creative Biolabs is pleased to share our cutting-edge technology and extensive expertise in immune checkpoint
protein development and conjugation/labeling to facilitate our clients' research and project development.
Creative Biolabs is uniquely positioned with our unparalleled, multiplexed antibody development platforms. Our comprehensive service portfolio includes discovering and developing polyclonal, monoclonal antibody, recombinant antibody fragments, antibody characterization, engineering, optimization, production, and manufacturing.
As a leading company in the drug development markets, Creative Biolabs possesses enriched
experience in offering a comprehensive range of customized small molecule drug development services to
accelerate your programs in a timely and cost-effective manner.
To meet the growing demands for validation of immune checkpoint drug candidates, Creative Biolabs has combined a range of cell-based assays with our state-of-the-art technology and in-depth knowledge to provide a series of immune checkpoint assays with high specificity and sensitivity. We can also work with our customers to design the personalized immune checkpoint assays to fulfill all specific requirements.
Equipped with world-leading technology platforms and professional scientific staff, Creative Biolabs is always dedicated to assisting our clients with the most satisfactory immune checkpoint antibody development services. Our custom services include polyclonal, monoclonal, recombinant antibody development, antibody characterization, engineering, optimization, production, and manufacturing to serve every unique need of our clients in immune checkpoint antibody development projects.
With decades of combined experience, highly skilled scientists at Creative Biolabs are ready to get started on your projects. A comprehensive collection of protein production and analysis services for recombinant affinity-tagged or native proteins is available at Creative Biolabs. In addition, we also offer customizable immune checkpoint protein development packages, including stable cell line development and immune checkpoint protein labeling services to meet downstream demands.
Targeted peptides, with various advantages, have great potential in immune checkpoint drug development. As a leader in immune checkpoint drug development, Creative Biolabs is your best partner. Our specialized and dedicated team is available to support our global clients with custom immune checkpoint-targeted peptides development services based on our unparalleled technology platform.
With ample experience in drug development and immune checkpoint research, Creative Biolabs is devoted to tailoring the best-fit proposal to screen and identify the desired small molecule candidates with expected functions for our global customers. Our comprehensive small molecule drug development strategies include structure-based drug design, NMR fragment-based drug discovery, organic synthesis, and high-throughput screening.
The development of predictive biomarkers is efficient for better treatment outcomes and fewer immune-related adverse events (irAEs). As a pioneer and undisputed global leader, Creative Biolabs is professional in developing advanced biomarkers for immune checkpoint inhibitor (ICI), including but not limited to genetic biomarker development, high-throughput analysis-based biomarker development, and translational biomarker assays.
Creative Biolabs has extensive experience in offering optimized preclinical research services for successful immune checkpoint drug discovery. Especially, we provide novel in vivo model development to ensure more reliable drug validation for immune checkpoint drug candidates. Also, we adjust our strategies to meet every specific requirement of global customers.